白皓宇,周珠贤,申有青

• 1:浙江大学化学工程与生物工程学院浙江省智能生物材料重点实验室

摘要(Abstract)：

精准控制药物释放是提高药物疗效并降低毒副作用的关键。触发式自释放系统可用于药物的程控和定点释放。研究构建一种触发式自释放的喜树碱(CPT)聚合物前药平台。通过开环易位聚合，合成一系列分子质量相近但氨基链长短/数量不同的聚合物前药(PEG_n-E_m-CPT_2和PEG_n-D_m-CPT_2)，重点探究氨基链长短/数量对CPT自释放的影响。结果表明，氨基链长短、数量和pH均可以改变CPT的释放行为。通过控制氨基数量，PEG_n-E_m-CPT_2和PEG_n-D_m-CPT_2在180h的释放量可分别从10%调控至89%或62%。此外，利用酸敏感性β-羧酸酰胺修饰氨基可实现酸触发CPT释放。该研究报道了利用邻近侧链氨基催化分子内水解现象来调控药物的释放性能。

关键词(KeyWords)： 触发式自释放;聚合物前药;喜树碱;释放调控

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划(2021YFA1201200);; 国家自然科学基金(52073249,21875211)

作者(Author): 白皓宇,周珠贤,申有青

参考文献(References)：

• [1] BOTELLA P, RIVERO-BUCETA E. Safe approaches for camptothecin delivery:Structural analogues and nanomedicines[J].Journal of Controlled Release, 2017, 247:28-54.
• [2] PASSERO F C, JR., GRAPSA D, SYRIGOS K N, et al. The safety and efficacy of Onivyde(irinotecan liposome injection)for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy[J]. Expert Review of Anticancer Therapy, 2016,16(7):697-703.
• [3] MATSUMURA Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect[J]. Advanced Drug Delivery Reviews, 2011, 63(3):184-192.
• [4] BURRIS H A, INFANTE J R, ANTHONY GRECO F, et al. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle[J]. Cancer Chemotherapy and Pharmacology, 2016, 77(5):1079-1086.
• [5] YURKOVETSKIY A V, FRAM R J. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer[J]. Advanced Drug Delivery Reviews, 2009, 61(13):1193-1202.
• [6] SCOTT L C, YAO J C, BENSON A B, et al. A phase II study of pegylated-camptothecin(pegamotecan)in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma[J]. Cancer Chemotherapy and Pharmacology,2009, 63(2):363-370.
• [7] GONZAGA R V, DO NASCIMENTO L A, SANTOS S S, et al. Perspectives about self-immolative drug delivery systems[J].Journal of Pharmaceutical Sciences, 2020, 109(11):3262-3281.
• [8] PETERSON G I, LARSEN M B, BOYDSTON A J. Controlled depolymerization:stimuli-responsive self-immolative polymers[J].Macromolecules, 2012, 45(18):7317-7328.
• [9] ALOUANE A, LABRUERE R, LE SAUX T, et al. Self-immolative spacers:Kinetic aspects, structure-property relationships, and applications[J]. Angewandte Chemie International Edition, 2015, 54(26):7492-7509.
• [10] KIM H, BROOKS A D, DILAURO A M, et al. Poly(carboxypyrrole)s that depolymerize from head to tail in the solid state in response to specific applied signals[J]. Journal of the American Chemical Society, 2020, 142(20):9447-9452.
• [11] ZHANG P, GAO D, AN K, et al. A programmable polymer library that enables the construction of stimuli-responsive nanocarriers containing logic gates[J]. Nature Chemistry, 2020, 12(4):381-390.
• [12] MENG X, GAO M, DENG J, et al. Self-immolative micellar drug delivery:The linker matters[J]. Nano Research, 2018, 11(12):6177-6189.
• [13] PORUBSKY M, GURSKA S, STANKOVA J, et al. AminoBODIPY conjugates for targeted drug delivery systems and real-time monitoring of drug release[J]. Molecular Pharmaceutics, 2021, 18(6):2385-2396.
• [14]徐昌活,周泉,祝鼎成,等.基于门舒特金反应的酶触发自降解高分子载体及其在基因输送中的应用[J].高分子学报,2017(6):937-945.XU C H, ZHOU Q, ZHU D C, et al. Esterase-activated self-immolative polymeric vector based on Menschutkin reaction for gene delivery[J]. Acta Polymerica Sinica, 2017(6):937-945.
• [15] DAL CORSO A, BORLANDELLI V, CORNO C, et al. Fast cyclization of a proline-derived self-immolative spacer improves the efficacy of carbamate prodrugs[J]. Angewandte Chemie International Edition, 2020, 59(10):4176-4181.
• [16] LEGIGAN T, CLARHAUT J, TRANOY-OPALINSKI I, et al. The first generation of beta-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy[J]. Angewandte Chemie International Edition, 2012,51(46):11606-11610.
• [17] ZHANG Y, YIN Q, YIN L, et al. Chain-shattering polymeric therapeutics with on-demand drug-release capability[J]. Angewandte Chemie International Edition, 2013, 52(25):6435-6439.
• [18] LIU G, WANG X, HU J, et al. Self-immolative polymersomes for high-efficiency triggered release and programmed enzymatic reactions[J]. Journal of the American Chemical Society, 2014, 136(20):7492-7497.
• [19] WANG Z, WU H, LIU P, et al. A self-immolative prodrug nanosystem capable of releasing a drug and a NIR reporter for in vivo imaging and therapy[J]. Biomaterials, 2017, 139:139-150.
• [20] FIFE T H, SINGH R, BEMBI R. Intramolecular general base catalyzed ester hydrolysis. The hydrolysis of 2-aminobenzoate esters[J]. Journal of Organic Chemistry, 2002, 67(10):3179-3183.
• [21] ZHOU Z X, MA X P, MURPHY C J, et al. Molecularly precise dendrimer-drug conjugates with tunable drug release for cancer therapy[J]. Angewandte Chemie International Edition, 2014, 53(41):10949-10955.
• [22] SU J K, JIN Z, ZHANG R, et al. Tuning the reactivity of cyclopropenes from living ring-opening metathesis polymerization(ROMP)to single-addition and alternating ROMP[J]. Angewandte Chemie International Edition, 2019, 58(49):17771-17776.
• [23] BARTHER D, MOATSOU D. Ring-opening metathesis polymerization of norbornene-based monomers obtained via the passerini three component reaction[J]. Macromolecular Rapid Communications, 2021, 42(9):e2100027.
• [24] GUTEKUNST W R, HAWKER C J. A General approach to sequence-controlled polymers using macrocyclic ring opening metathesis polymerization[J]. Journal of the American Chemical Society, 2015, 137(25):8038-8041.
• [25] VARLAS S, FOSTER J C, O'REILLY R K. Ring-opening metathesis polymerization-induced self-assembly(ROMPISA)[J].Chemical Communications, 2019, 55(62):9066-9071.
• [26] KAMMEYER J K, BLUM A P, ADAMIAK L, et al. Polymerization of protecting-group-free peptides via ROMP[J]. Polymer Chemistry, 2013, 4(14):3929-3933.
• [27] LEITGEB A, WAPPEL J, SLUGOVC C. The ROMP toolbox upgraded[J]. Polymer, 2010, 51(14):2927-2946.
• [28] BRAY F, FERLAY J, SOE RJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Ca-a Cancer Journal for Clinicians, 2018, 68(6):394-424.
• [29] SHEN Y, ZHOU Z, SUI M, et al. Charge-reversal polyamidoamine dendrimer for cascade nuclear drug delivery[J]. Nanomedicine:Nanotechnology, Biology, and Medicine, 2010, 5(8):1205-1217.
• [30] XU P, VAN KIRK E A, ZHAN Y, et al. Targeted charge-reversal nanoparticles for nuclear drug delivery[J]. Angewandte Chemie International Edition, 2007, 46(26):4999-5002.
• [31] DUNCAN R, IZZO L. Dendrimer biocompatibility and toxicity[J]. Advanced Drug Delivery Reviews, 2005, 57(15):2215-2237.